CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Drug Reimbursement Recommendation - teduglutide

Published on: November 21, 2019
Result type: News

Today, CADTH has issued final recommendations for:

teduglutide (Revestive)

Indications: Short Bowel Syndrome (SBS), pediatrics
Recommendation: Reimburse with clinical criteria and/or conditions

For more information